Clinical trials recruiting for Metastatic Castration-Resistant Prostate Cancer (mCRPC)
18
Recruiting trials
37
US states with sites
47
Countries
0%
Accept healthy volunteers
Phase breakdown
Drugs and treatments being studied
Where trials are recruiting (top US states)
| State | Recruiting trials |
|---|---|
| California | 10 |
| Texas | 9 |
| Colorado | 7 |
| Arizona | 6 |
| New York | 6 |
| Virginia | 6 |
| Florida | 5 |
| Illinois | 5 |
| Minnesota | 5 |
| Ohio | 5 |
| Pennsylvania | 5 |
| South Carolina | 5 |
Top cities
Duarte, California 5Houston, Texas 5Charlottesville, Virginia 4Dallas, Texas 4Los Angeles, California 4Myrtle Beach, South Carolina 4Nashville, Tennessee 4New York, New York 4Philadelphia, Pennsylvania 4San Francisco, California 4
Self-screener
Recruiting trials
- 3D1015 Injection for Patients With mCRPC
- A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001)
- A Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With mCRPC
- A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
- A Study of NX-1607 in Adults With Advanced Malignancies
- A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
- A Study to Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Metastatic Prostate Cancer
- A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors
- AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC)
- Cannabidiol for Pain Relief of Patients With End-stage mCRPC
- Combination Study of Antibiotics With Enzalutamide (PROMIZE)
- Exploring Auger-Enhanced PSMA-Targeted Radioligand Therapy: A First-in-Taiwan Clinical Study of 161Tb-PSMA-I&T
- Green Tea and Quercetin in Combination With Docetaxel Chemotherapy in Castration-resistant Prostate Cancer Patients
- Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T
- ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer
- REGN15505 (PSMAx4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in Adult Patients With Metastatic Castration-Resistant Prostate Cancer and Clear Cell Renal Cell Carcinoma
- Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer
Related conditions
Trials recruiting for Metastatic Castration-Resistant Prostate Cancer (mCRPC) often also study these conditions. Each links to its own recruiting-trial list.
Prostate cancer 1234Lung cancer 2180Clear Cell Renal Cell Carcinoma (ccRCC) 5Non-small cell lung cancer 507Colorectal cancer 1359Urothelial Carcinoma (UC) 5Triple Negative Breast Cancer (TNBC) 35Small Cell Lung Cancer (SCLC) 29Renal Cell Carcinoma (RCC) 10Prostatic Neoplasms 36
Common questions
Are these trials free to join?
Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.
How do I know if I am eligible for Metastatic Castration-Resistant Prostate Cancer (mCRPC) trials?
Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.
Is this list complete?
No. For the full list, search ClinicalTrials.gov.